MyMD Pharmaceuticals Enrolls First Person in Stage 2 Medical Trial of MYMD-1 as a Treatment for Delaying Aging and Increasing Healthy And Balanced Life-span

MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals Inc (” MyMD” or “the Company”), a clinical stage pharmaceutical firm devoted to prolonging healthy and balanced life-span, today announced that the initial individual has actually been enrolled in the Company’s Phase 2 professional trial of lead prospect MYMD-1, a dental immune regulator medication, as a treatment for postponing aging as well as increasing healthy life expectancy.

The primary endpoint for the Stage 2 double-blind, placebo-controlled clinical test is to accomplish a decrease in the distributing degrees of (TNF-α), lump necrosis factor receptor I (TNFRI) and IL-6. TNF-α and also IL-6 are the proteins in the body that cause swelling and also assist turn on the process of aging. The secondary steps of the test will certainly be the safety and security, tolerability, as well as pharmacokinetics in this populace of patients.

” In a Phase 1 professional trial of MYMD-1, we demonstrated the medicine’s statistically significant efficacy in minimizing levels of TNF-α, a key player in creating pathological aging, in the blood. The FDA has approved TNF-α reduction as the primary endpoint for our Phase 2 research, which our team believe positions us well for an effective Stage 2 result,” stated Chris Chapman, M.D., President, Supervisor as well as Principal Medical Officer of MyMD. “The initiation of person registration in this research advances our mission to slow the aging procedure, protect against loss of muscle mass cells in aging, limitation frailty, and expand healthy life-span.”

MyMD has actually stated that there are no FDA-approved drugs for treating aging conditions and expanding healthy life-span people, a market anticipated to be a minimum of $600 billion by 20251 according to a major financial investment bank. TNF-α blockers are one of the most recommended drugs by profits, a global market of approximately $40 billion annually,2 as well as, according to Nature Aging journal,3 a stagnation in maturing that would raise life span by one year is worth $38 trillion as well as by 10 years deserves $367 trillion.

In addition to aging, MYMD-1’s unique action in regulating the body immune system and also dealing with persistent swelling is being created for the treatment of autoimmune condition, including rheumatoid joint inflammation (RA), multiple sclerosis (MS), diabetic issues, and also inflammatory digestive tract illness.

” We plan to begin composing procedures for a Phase 2 pilot study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman kept in mind. “The increasing prevalence of rheumatoid joint inflammation and various other autoimmune as well as inflammatory diseases are driving demand for TNF inhibitors like MYMD-1, and our company believe our orally administered medicine with extremely low poisoning would certainly be turbulent to the $60 billion market for RA if authorized by the FDA for this indicator.”

Rheumatoid joint inflammation impacts about 40 million people worldwide.4.

Regarding MYMD-1.

Originally created for autoimmune conditions, MYMD-1’s main function is to slow down the aging process, protect against sarcopenia and frailty, and expand healthy life-span. Due to the fact that it can cross the blood-brain barrier and also gain access to the main nerve system (CNS), MYMD-1 is additionally placed to be a feasible treatment for brain-related disorders. Its device of action and also efficiency in conditions consisting of numerous sclerosis (MS) and thyroiditis have been examined with collaborations with several scholastic organizations. MYMD-1 is additionally revealing guarantee in pre-clinical research studies as a possible treatment for message- COVID-19 problems and also as an anti-fibrotic as well as anti-proliferation restorative.

MYMD-1 has revealed efficiency in pre-clinical research studies in regulating the immune system by carrying out as a selective inhibitor of tumor death factor-alpha (TNF-α), a vehicle driver of persistent swelling. Unlike other therapies, MYMD-1 has actually been shown in these pre-clinical studies to uniquely block TNF-α when it becomes overactivated in autoimmune illness and cytokine storms, however not obstruct it from doing its regular job of being a very first responder to any type of regular sort of modest infection. MYMD-1’s ease of dental dosing is one more differentiator contrasted to presently readily available TNF-α blockers, all of which require delivery by injection or mixture. No authorized TNF inhibitor has ever been dosed by mouth. Additionally, the medication is not immunosuppressive as well as has not been shown to create the major adverse effects common with typical therapies that treat inflammation.

Concerning MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a professional stage pharmaceutical company dedicated to prolonging healthy and balanced life-span, is focused on developing two novel restorative platforms that treat the causes of condition as opposed to only dealing with the signs. MYMD-1 is a drug system based on a scientific stage small molecule that manages the body immune system to control TNF-α, which drives chronic inflammation, as well as various other pro-inflammatory cell signaling cytokines. MYMD-1 is being created to delay aging, rise long life, as well as treat autoimmune conditions and COVID-19- linked depression. The Company’s second drug system, Supera-CBD, is being developed to treat chronic discomfort, addiction and also epilepsy. Supera-CBD is an unique artificial derivative of cannabidiol (CBD) as well as is being created to address and improve upon the quickly growing CBD market, that includes both FDA approved medicines and also CBD products not currently regulated as medications. For more information, see www.mymd.com.